Champions Oncology Set to Announce Earnings on March 11
CHAMPIONS ONCOLOGY ($CSBR) is anticipated to release its quarterly earnings on Tuesday, March 11th, before the market opens, according to Finnhub. Analysts forecast revenues of $13,190,640 and earnings of -$0.01 per share.
For comprehensive insights, visit Quiver Quantitative’s $CSBR Stock page, where you can track insider trading, hedge fund activities, congressional trading, and more.
Recent Hedge Fund Activity for Champions Oncology
In the latest quarter, 10 institutional investors have increased their stakes in CHAMPIONS ONCOLOGY, while 8 have reduced their holdings. Notably, several significant share adjustments were made:
- TOCQUEVILLE ASSET MANAGEMENT L.P. cut 96,299 shares (-13.7%) from its portfolio in Q4 2024, representing about $825,282.
- GOLDMAN SACHS GROUP INC eliminated 48,413 shares (-100.0%) in Q4 2024, valued at approximately $414,899.
- RENAISSANCE TECHNOLOGIES LLC added 18,848 shares (+15.7%) to its portfolio in Q4 2024, worth an estimated $161,527.
- MORGAN STANLEY increased its holdings by 15,100 shares (+26.1%) in Q4 2024, equaling around $129,407.
- NORTHERN TRUST CORP brought in 12,923 shares (+31.5%) during the same quarter, estimated at $110,750.
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 11,524 shares (+inf%) in Q4 2024, valued at $98,760.
- VIRTU FINANCIAL LLC acquired 11,051 shares (+inf%) in Q4 2024, with an estimated value of $94,707.
To monitor the investment strategies of hedge funds, explore Quiver Quantitative’s institutional holdings dashboard.
This article is not financial advice. For more details, please refer to Quiver Quantitative’s disclaimers. Be aware that there may be inaccuracies due to ticker-mapping errors and other anomalies.
This article was originally published on Quiver News. To read the full story, click here.
The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Nasdaq, Inc.
